Civardi G, Vallisa D, Bertè R, Lazzaro A, Moroni C F, Cavanna L
1a Divisione di Medicina ed Ematologia, Programma Oncologia Ematologia, Azienda USL di Piacenza, Ospedale Civile, V. Taverna, 49, 29100 Piacenza, Italy.
Eur J Cancer. 2002 Dec;38(18):2382-7. doi: 10.1016/s0959-8049(02)00481-1.
Imaging techniques like ultrasonography (US) or computed tomography (CT) allow full liver scanning and the accurate detection of focal lesions of the liver parenchyma. The occurrence of such lesions in concomitance with non-Hodgkin's lymphoma (NHL), both at the onset of the disease and during follow-up, is of great significance, because it affects staging, prognosis and therapeutic choices. Moreover, the occurrence of focal liver lesions in the setting of a lymphoma is generally considered to be a marker of liver involvement. Nonetheless, data on the prevalence and clinical significance of focal liver lesions occurring in these clinical conditions are limited. Therefore, we retrospectively evaluated the prevalence, nature and clinical significance of focal liver lesions diagnosed by imaging techniques (US and CT) in 414 consecutive NHL patients. The nature of the lesions was established either by US-guided biopsy or by evaluation of the response to chemotherapy for the underlying disease and confirmed by clinical and US follow-up. Subtype of NHL (aggressive or indolent) and Hepatitis C virus (HCV) status were also considered. We detected 129 focal liver lesions (76 at onset and 53 during the follow-up). Hepatic involvement by NHL was found in 69 cases (53%). We observed 7 cases of Hepatocellular Carcinoma (HCC) and 3 cases of metastasis. At onset, only 39% of the detected lesions were due to lymphoma and 58% were benign. Conversely, 74% of the liver lesions detected during the follow-up were due to NHL while 15% to a malignancy other than NHL. All HCC cases occurred in HCV-positive patients with chronic liver disease. We concluded that the focal liver lesions detected at onset in NHL patients are frequently benign and unrelated to the underlying disease. Conversely, most focal liver lesions detected during the follow-up period are malignant and the possibility of HCC occurrence in HCV-positive patients should always be considered. Therefore, these lesions should undergo a full diagnostic work-up, including US-guided biopsy.
超声检查(US)或计算机断层扫描(CT)等成像技术可对肝脏进行全面扫描,并准确检测肝实质的局灶性病变。在非霍奇金淋巴瘤(NHL)发病时及随访期间,此类病变与NHL同时出现具有重要意义,因为它会影响分期、预后及治疗选择。此外,淋巴瘤患者出现肝脏局灶性病变通常被视为肝脏受累的标志。然而,关于这些临床情况下肝脏局灶性病变的患病率及临床意义的数据有限。因此,我们回顾性评估了414例连续NHL患者通过成像技术(US和CT)诊断出的肝脏局灶性病变的患病率、性质及临床意义。病变性质通过US引导下活检或对基础疾病化疗反应的评估来确定,并通过临床及US随访得以证实。同时也考虑了NHL的亚型(侵袭性或惰性)及丙型肝炎病毒(HCV)状态。我们共检测到了129处肝脏局灶性病变(发病时76处,随访期间53处)。69例(53%)患者发现有NHL肝脏受累。我们观察到7例肝细胞癌(HCC)和3例转移瘤。发病时,检测到的病变中仅39%由淋巴瘤引起,58%为良性。相反,随访期间检测到的肝脏病变中74%由NHL引起,15%由NHL以外的恶性肿瘤引起。所有HCC病例均发生在患有慢性肝病的HCV阳性患者中。我们得出结论,NHL患者发病时检测到的肝脏局灶性病变通常为良性,与基础疾病无关。相反,随访期间检测到的大多数肝脏局灶性病变为恶性,应始终考虑HCV阳性患者发生HCC的可能性。因此,这些病变应进行全面的诊断检查,包括US引导下活检。